The Latin America, Middle East and Africa Telmisartan Market would witness market growth of 6.9% CAGR during the forecast period (2020-2026). Telmisartan is also known as Micardis. Similar to the ARBs, telmisartan is available across in different combination tablets. Telmisartan is equally as efficient as olmesartan in reducing blood pressure.
In addition to reducing blood pressure, telmisartan offers two other advantages: reducing blood sugar levels (by increasing insulin sensitivity) and decreasing cholesterol levels. The included blood sugar advantage makes telmisartan different from losartan & olmesartan. All these factors will support the growth of the telmisartan market during the forecast period.
The growth of the market would experience a boost due to the rising awareness about hypertension and its management by organizing global campaigns. For example, in May 2017, the Argentinian Society of Hypertension (SAHA) took participation in global campaigns like ‘May Measurement Month and World Hypertension Day’ with an aim to spread awareness among people about high blood pressure and its management.
The Hospital Pharmacies market dominated the Saudi Arabia Telmisartan Market by Distribution Channel in 2019, thereby, achieving a market value of $34.3 million by 2026. The Drug Stores and Retail Pharmacies market is estimated to grow at a CAGR of 7.7% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: Telmisartan Market in LAMEA is expected to register a CAGR of 6.9% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Hypertension
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Telmisartan Market, by Indication
1.4.2 LAMEA Telmisartan Market, by Distribution Channel
1.4.3 LAMEA Telmisartan Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Telmisartan Market by Indication
3.1 LAMEA Hypertension Market by Country
3.2 LAMEA Cardiovascular Risk Reduction Market by Country
Chapter 4. LAMEA Telmisartan Market by Distribution Channel
4.1 LAMEA Hospital Pharmacies Market by Country
4.2 LAMEA Drug Stores and Retail Pharmacies Market by Country
4.3 LAMEA Online Pharmacies Market by Country
Chapter 5. LAMEA Telmisartan Market by Country
5.1 Brazil Telmisartan Market
5.1.1 Brazil Telmisartan Market by Indication
5.1.2 Brazil Telmisartan Market by Distribution Channel
5.2 Argentina Telmisartan Market
5.2.1 Argentina Telmisartan Market by Indication
5.2.2 Argentina Telmisartan Market by Distribution Channel
5.3 UAE Telmisartan Market
5.3.1 UAE Telmisartan Market by Indication
5.3.2 UAE Telmisartan Market by Distribution Channel
5.4 Saudi Arabia Telmisartan Market
5.4.1 Saudi Arabia Telmisartan Market by Indication
5.4.2 Saudi Arabia Telmisartan Market by Distribution Channel
5.5 South Africa Telmisartan Market
5.5.1 South Africa Telmisartan Market by Indication
5.5.2 South Africa Telmisartan Market by Distribution Channel
5.6 Nigeria Telmisartan Market
5.6.1 Nigeria Telmisartan Market by Indication
5.6.2 Nigeria Telmisartan Market by Distribution Channel
5.7 Rest of LAMEA Telmisartan Market
5.7.1 Rest of LAMEA Telmisartan Market by Indication
5.7.2 Rest of LAMEA Telmisartan Market by Distribution Channel
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.2.4.2 Acquisition and Mergers:
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Approvals:
6.3.5.2 Partnerships, Collaborations, and Agreements:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Approvals:
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Product Launches and Product Expansions:
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Approvals:
6.8.5.2 Product Launches and Product Expansions:
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Approvals:
6.9.5.2 Product Launches and Product Expansions:
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Approvals:
TABLE 1 LAMEA Telmisartan Market, 2016 - 2019, USD Million
TABLE 2 LAMEA Telmisartan Market, 2020 - 2026, USD Million
TABLE 3 LAMEA Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 4 LAMEA Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 5 LAMEA Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 6 LAMEA Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 7 LAMEA Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 8 LAMEA Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 9 LAMEA Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 10 LAMEA Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 11 LAMEA Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 12 LAMEA Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 13 LAMEA Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 14 LAMEA Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 15 LAMEA Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 16 LAMEA Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 17 LAMEA Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 18 LAMEA Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 19 Brazil Telmisartan Market, 2016 - 2019, USD Million
TABLE 20 Brazil Telmisartan Market, 2020 - 2026, USD Million
TABLE 21 Brazil Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 22 Brazil Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 23 Brazil Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 24 Brazil Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 25 Argentina Telmisartan Market, 2016 - 2019, USD Million
TABLE 26 Argentina Telmisartan Market, 2020 - 2026, USD Million
TABLE 27 Argentina Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 28 Argentina Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 29 Argentina Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 30 Argentina Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 31 UAE Telmisartan Market, 2016 - 2019, USD Million
TABLE 32 UAE Telmisartan Market, 2020 - 2026, USD Million
TABLE 33 UAE Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 34 UAE Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 35 UAE Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 36 UAE Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 37 Saudi Arabia Telmisartan Market, 2016 - 2019, USD Million
TABLE 38 Saudi Arabia Telmisartan Market, 2020 - 2026, USD Million
TABLE 39 Saudi Arabia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 40 Saudi Arabia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 41 Saudi Arabia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 42 Saudi Arabia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 43 South Africa Telmisartan Market, 2016 - 2019, USD Million
TABLE 44 South Africa Telmisartan Market, 2020 - 2026, USD Million
TABLE 45 South Africa Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 46 South Africa Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 47 South Africa Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 48 South Africa Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 49 Nigeria Telmisartan Market, 2016 - 2019, USD Million
TABLE 50 Nigeria Telmisartan Market, 2020 - 2026, USD Million
TABLE 51 Nigeria Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 52 Nigeria Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 53 Nigeria Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 54 Nigeria Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 55 Rest of LAMEA Telmisartan Market, 2016 - 2019, USD Million
TABLE 56 Rest of LAMEA Telmisartan Market, 2020 - 2026, USD Million
TABLE 57 Rest of LAMEA Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 58 Rest of LAMEA Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 59 Rest of LAMEA Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 60 Rest of LAMEA Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 61 Key Information – Abbott Laboratories
TABLE 62 key information – Aurobindo Pharma Limited
TABLE 63 Key Information – Boehringer Ingelheim International GmbH
TABLE 64 Key Information – Cipla Limited
TABLE 65 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 66 Key Information – Mylan N.V.
TABLE 67 Key Information – Sanofi S.A.
TABLE 68 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Cadila Healthcare Ltd.
List of Figures
FIG 1 Methodology for the research